compounded semaglutide or tirzepatide Program: Results, Timeline & Comparison Learn more about GLP 1

Target 80-100 ounces of fluid daily, primarily water

UK approval will likely follow that, so realistic availability is 2027 at the earliest and with private prescription first

This product has not been evaluated by the FDA or any regulatory authority for medical use

Ohio State University: GLP-1 and Other Weight Loss Medications Bajaj H et al

Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability)

To find out whether semaglutide is included in your insurance coverage, contact your insurance plan directly or review your plans drug formulary, which lists all of the drugs covered by your plan